69results about How to "Reduce brain damage" patented technology

Portable external gravity-based devices and methods for regulating cerebral spinal fluid drainage from brain, tissue or organs of a patient, and methods for reducing secondary brain injury to a patient by externally regulating the amount of gravity-based cerebral spinal fluid drainage from brain or spine are provided by this invention.

Compositions and methods for enhancing vascular integrity in animals are disclosed. The compositions and methods, which utilize long chain polyunsaturated fatty acids and nitric oxide releasing compounds are also effective for reducing ischemia-induced brain injury in an animal.

The present invention is directed to the novel use of a class of peptide compounds for treating status epilepticus or related conditions, e.g. acute repetitive seizures, seizure clusters, etc.

A cervical immobilization collar incorporates one or more cooling elements for inducing a mild cerebral hypothermia by transcutaneous cooling of oxygenated blood flowing through carotid arteries. The immobilization collar includes an annular support structure having an extended axial length for limiting cervical compaction of a wearer's neck and a chin rest for limiting cervical rotation of the wearer's neck. In addition, the one or more cooling elements, which function as a heat extractor, are carried by the support structure in positions for inducing transcutaneous conduction of heat through an anterior portion of the wearer's neck from at least one of the wearer's carotid arteries.

The invention belongs to the technical field of medicine, and concretely relates to caffeoyl substituted pentacyclic triterpenoid derivatives as shown in a formula I and a purpose thereof in preparing medicaments or health products for preventing and treating brain injury and / or neurological dysfunction and / or cognitive dysfunction caused by cerebral ischemia, hypoglycemia and cerebral anoxia. Experiments verify that the derivatives is capable of protecting nerve cells under conditions of hypoglycemia and hypoxia, can substantially improve neurological damage induced by cerebral ischemia, and thus is expected to be developed as medicaments for preventing and treating the brain injury caused by the cerebral ischemia, the hypoglycemia and the cerebral anoxia as well as improving corresponding neuroethology functions.

The invention provides a pharmaceutical composition useful in treating cerebral ischemia and traumatic cerebral injury. The pharmaceutical composition is also useful as a prophylactic treatment during surgical procedures wherein the potential for ischemic tissue damage is present. Also included in the invention is a method for preparing the pharmaceutical composition, as well as methods for treatment.

A concussive reduction helmet attachment system which reduces the total area available for acceleration of the head in all axis, specifically designed to provide a measured reduction in accelerative force at the critical moment within the blow. A helmet attachment that reduces the factors that contribute to mechanical transfer of energy to the brain thereby reducing potential traumatic brain injury, concussions and neck compression. A helmet augmentation for body-contact sport helmets, also having utility for military ground based personnel helmets where blunt force trauma injury to the head and neck are apt to occur. A concussive helmet attachment having a Translational Axial Rotation Control Bracing System (TARCBS) that transfers mechanical energy to the torso, reduces available area for linear and rotational acceleration while reducing potential for neck and spinal injury. A concussive helmet attachment having two construction types, single and multiple component and three embodiments: hard, soft and mechanical.

The invention relates to the prophylactic and therapeutic applications of certain estrogenic components, such as estetrol, in neurological disorders, such as neonatal hypoxic-ischemic encephalopathy (HIE).

An improved design for a helmet to reduce injuries caused by helmet-to-helmet collisions. Certain embodiments include novel quick release features that permit the detachment of a facemask from a helmet in 30 seconds or less, resulting in the ability to attend to an injured player in a rapid fashion and without the need for any additional tools to accomplish such removal. Other aspects relate to impact energy absorbing constructions, including shock absorbing systems and PEEK facemask designs, that when combined with the quick release features described, provide a superior helmet for a player's protection.

The invention discloses an effective part extract of valeriana amurensis P.Smirn. and a quality control method and medical use thereof. The content of total lignanoid substances in the extract accounts for over 50 percent of the total weight of the extract, wherein (+) pinoresinol-4,4'-O-beta-D-diglucopyranoside and (+) pinoresinol-8-O-beta-D-glucopyranoside are the main active components in the effective part extract, and the sum of the contents of the two active components accounts for more than 13 percent of the total weight of the extract. The invention also discloses a preparation method and the quality control method of the effective part extract. The effective part extract contains one effective part group of total lignanoid components and can effectively treat central nervous system degenerative diseases including senile dementia, tristimania and the like. The process for preparing the effective part extracts of the valeriana amurensis P.Smirn. for resisting the senile dementia can adapt to industrial production, and provides a new method for treating the central nervous system degenerative diseases by using the valeriana amurensis P.Smirn..

A curtain airbag of a vehicle is provided adjacent to the roof of the vehicle in a folded state, is configured to have a shape that unfolds downward between an inner side surface of the vehicle and an occupant when the vehicle crashes, and includes an outer panel that proceeds toward the side surface of the vehicle and an inner panel that proceeds toward the occupant upon expansion. The curtain airbag further includes a head support part configured to have a shape in which an expansion thickness, which is defined by the outer panel and the inner panel in a portion that the head of the occupant contacts due to the car crash, gradually increases toward the front of the vehicle, so as to prevent the head of the occupant from rotating while moving toward the front of the vehicle. The curtain airbag may effectively stop the head of the occupant from rotating while moving toward the front of the vehicle during a vehicle crash.

The present invention belongs to the field of pharmaceutical technology and relates to transdermal Ligustrazine plaster and its preparation. It has Ligustrazine phosphate or Ligustrazine as active medicinal component and consists of medicine storing back, adhering layer, release controlling film, back lining layer and protective layer. It is superior to available Ligustrazine preparation forms inmedicine releasing are, transdermal rate and lasting release time, and has the features of determined curative effect, stable quality, high safety, etc. Animal experiments show that the plaster can retard the effect of ischemic to cerebral damage, inhibit thrombosis caused by tissue damage, prevent and treat cerebral embolism and maintain balanced medicine density in blood for 24 hr; and has light irritation to skin, no irritability and no toxic reaction.

The invention relates to the prophylactic and therapeutic applications of certain estrogenic components, such as estetrol in neurological disorders, such as diffuse white matter injury.

A system for rapid induction of indication of hypothermia especially of the heart and brain during cardiac arrest and normal circulation. The device recirculates blood through an extracorporeal circuit using a single venous access. The blood can be cooled and / or treated before reentry to the vascular system. The device maximizes the cooling rate by optimizing the blood withdrawal rate. Cooling of the brain is achieved by flow of cooled blood from the thorax to the head. During cardiac arrest, the blood flow is generated by cardiopulmonary resuscitation.

The invention discloses a small molecule polypeptide and an application thereof in preparing a medicine for preventing and treating ischemic stroke. By synthesizing a TAT protein transduction domain,the protein polypeptide of CDK5 and the fusion protein TAT-CDK5-CTM of the autophagy targeted motif CTM can be combined and inhibited, the TAT is used to carry the CDK5 protein polypeptide, which is transported by blood through a blood cerebral barrier, and is taken up by neurons. The peptide is applied to in-vitro and in-vivo ischemic stroke models to effectively block the bonding effect of the NR2B subunit of a N-methyl aspartate receptor (NMDAR) and the cyclin-dependent protein kinase 5 (CDK5), the CTM mediates the polypeptide molecules which are bonded with CDK5 protein to enter lysosomalfor degradation, neuronal apoptosis and necrosis induced by CDK5 downstream can be inhibited, brain damage after ischemic stroke can be reduced, and the application provides a molecular target for thedevelopment of drugs for the treatment of ischemic stroke.

A method to reduce brain injury and brain swelling includes performing active compression decompression cardiopulmonary resuscitation on an individual in a supine position. The individual's head, shoulders, and heart are elevated relative to the individual's lower body. The head is elevated to a height of between about 20 cm and 30 cm above the horizontal plane and the heart is elevated to a height of between about 3 cm and 10 cm above the horizontal plane. Chest compressions are performed on the individual and actively decompressing the individual's chest while the individual's head, shoulders, and heart are elevated. Intrathoracic pressure of the individual is regulated using an intrathoracic pressure regulation device both while the individual is in the supine position and while the individual's head, shoulders, and heart are elevated relative to the lower body, thereby reducing brain edema during CPR.

One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and / or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free fatty acids, and identifying compounds suitable for treatment or prevention of ROS-mediated injury are also disclosed.

A system for rapid induction of indication of hypothermia especially of the heart and brain during cardiac arrest and normal circulation. The device recirculates blood through an extracorporeal circuit using a single venous access. The blood can be cooled and / or treated before reentry to the vascular system. The device maximizes the cooling rate by optimizing the blood withdrawal rate. Cooling of the brain is achieved by flow of cooled blood from the thorax to the head. During cardiac arrest, the blood flow is generated by cardiopulmonary resuscitation.

The invention discloses medicinal application of ethyl acetate extracts from Gastrodia elata Blume in treating ischemic cerebrovascular disease. The Gastrodia elata Blume is ground, extracted by ethanol, and is concentrated under reduced pressure to obtain an ethanol extract; the ethanol extract is extracted by ethyl acetate, and the ethyl acetate is concentrated and recovered to mainly obtain a group of phenol components; and total phenols or a single phenol component contained in the extracts is used for preparing medicaments for treating the ischemic cerebrovascular disease. The medicaments can be prepared into preparations such as tablets, pills, granules, capsules, oral liquid, paste and the like; and the phenol components have the effect of protecting brain by reducing lipid peroxidation and lightening calcium overload, and play an important role in preventing and treating the ischemic cerebrovascular disease.

The present invention relates to the treatment or prevention of glutamatergic toxicity by the administration of effective amounts of branched chain α-keto acids alone or in combination with other antiglutamate agents such as L-methionine S-sulfoximine, L-ethionine S-sulfoximine, and glufosinate. In particular, the present invention relates to the treatment or prevention of diseases or conditions which are characterized by increased levels of brain neuronal glutamate.

A cervical immobilization collar incorporates one or more cooling elements for inducing a mild cerebral hypothermia by transcutaneous cooling of oxygenated blood flowing through carotid arteries. The immobilization collar includes an annular support structure having an extended axial length for limiting cervical compaction of a wearer's neck and a chin rest for limiting cervical rotation of the wearer's neck. In addition, the one or more cooling elements, which function as a heat extractor, are carried by the support structure in positions for inducing transcutaneous conduction of heat through an anterior portion of the wearer's neck from at least one of the wearer's carotid arteries.

The invention provides new uses, compositions and methods of administration for specific binding agents to von Wiliebrand Factor (vWF) in patients with thromboembolic disorders and in particular new combined uses with thrombolytic agents such as tissue plasminogen activator in patients with thromboembolic disorders such as e.g. ischemic stroke. Furthermore, a new group of vWF binding agents and an improved Middle Cerebral Artery Thrombosis Model in guinea pigs to study the effects of stroke such as ischemia (oxygen and glucose depriviation) and hemorrhage (bleeding), in particular hemorrhage, are provided.

The invention provides a soluble honokiol detivative (such as a water soluble honokiol derivative) and its application in antagonizing glycoprotein VI receptor and providing antioxidant and neuroprotective effects.

The invention belongs to the field of pharmaceutical chemistry and specifically relates to a paeoniflorin compound with an inhibitory activity against abnormal expression of cyclooxygenase-2, a synthetic method thereof and an application in preparation of nonsteroidal anti-inflammatory drugs and drugs for treating and preventing cerebral apoplexy and / or Parkinson's disease. The paeoniflorin compound has a structure as shown in the following general formula I.

One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and / or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free fatty acids, and identifying compounds suitable for treatment or prevention of ROS-mediated injury are also disclosed.

The invention provides application of hydrogen sulfide modified mesenchymal stem cells (MSCs) extracellular vesicles (EVs) serving as a miRNA delivery vector to hypoxic-ischemic brain damage (HIBD). According to the application, it is discovered and proved by first research that the curative effect of miR-7b-5p in HIBD can be effectively improved by adopting H2S to pretreat MSCs EVs. Specifically,through research, it is found that H2S-EVs can be adopted to serve as a natural excellent vector of miR-7b-5p, and exerts the better neuroprotection effect in HIBD; and meanwhile, by inhibiting expression of a target gene FOS, HI-induced brain damage and related neuroinflammation can be effectively relieved.

The present invention relates to activated neurotensin, pharmaceutical compositions comprising the same, and the uses thereof. The compounds and compositions of the invention may be used e.g., to reduce body temperature, attenuate or halt seizures, reduce excitotoxicity, promote neuroprotection, reduce neuroinflammation and aberrant axonal sprouting or reduce pain.

The present invention relates to a composition for treating inflammatory brain diseases which includes a stem cell as an active ingredient. When the stem cell according to the present invention is directly administered to animal models with inflammatory brain diseases, a brain damage caused by inflammation such as edema is significantly reduced, the weight-loss phenomenon is greatly improved, and the like, and thus the cell has an excellent effect in treating inflammatory brain diseases and consequently can be used effectively in treating inflammatory brain diseases.

One aspect of the present invention relates to a method of treating or preventing pathologic effects of hyperglycemia and / or increased fatty acid flux in a subject in need of such treatment or preventive therapy. This method involves administering a composition containing a therapeutically effective amount of a ROS inhibitor to a subject in need thereof.

The invention relates to the use of morin and mangiferin, the pharmaceutically acceptable salts, prodrugs and / or solvates thereof in the production of a pharmaceutical composition for the prevention and / or treatment of a neurodegenerative disease and symptoms associated with ageing, as well as to food compositions comprising said compounds.